MedPath

Glucagon

Generic Name
Glucagon
Brand Names
Baqsimi, Glucagen, Gvoke, Ogluo
Drug Type
Biotech
CAS Number
16941-32-5
Unique Ingredient Identifier
76LA80IG2G
Background

Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia. Glucagon raises blood sugar through activation of hepatic glucagon receptors, stimulating glycogenolysis and the release of glucose.

Glucagon was granted FDA approval on 14 November 1960.

Indication

Glucagon is indicated as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia.

Associated Conditions
Severe Hypoglycemia
Clinical Trials
Related News

Glucagon Ready-to-Use (RTU) for Prevention of Exercise-Induced Hypoglycemia During Aerobic Exercise in Adults With T1D

Phase 2
Completed
Conditions
Hypoglycemia
Interventions
Drug: Glugaon RTU Injection Without Insulin Pump Reduction
Other: Vehicle for Glucagon RTU Injection With Insulin Pump Reduction
First Posted Date
2019-02-15
Last Posted Date
2023-08-25
Lead Sponsor
Xeris Pharmaceuticals
Target Recruit Count
48
Registration Number
NCT03841526
Locations
🇨🇦

LMC Clinical Research Inc, Toronto, Ontario, Canada

Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male Volunteers

Not Applicable
Completed
Conditions
Cardiovascular Diseases
Interventions
Drug: Saline 0.9%
First Posted Date
2019-02-08
Last Posted Date
2024-04-03
Lead Sponsor
Cambridge University Hospitals NHS Foundation Trust
Target Recruit Count
26
Registration Number
NCT03835013
Locations
🇬🇧

Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom

Glucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric Surgery

Phase 2
Completed
Conditions
Hyperinsulinemic Hypoglycemia
Interventions
Other: Placebo
First Posted Date
2018-12-10
Last Posted Date
2020-05-21
Lead Sponsor
Xeris Pharmaceuticals
Target Recruit Count
14
Registration Number
NCT03770637
Locations
🇺🇸

University of Colorado-Denver, Aurora, Colorado, United States

🇺🇸

Mayo Clinic- Rochester, Rochester, Minnesota, United States

🇺🇸

Duke Early Phase Clinical Research, Durham, North Carolina, United States

and more 2 locations

G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes

Phase 3
Completed
Conditions
Insulin Hypoglycemia
Type 1 Diabetes Mellitus
Severe Hypoglycemia
Interventions
Drug: Novo Glucagon
First Posted Date
2018-11-13
Last Posted Date
2020-05-22
Lead Sponsor
Xeris Pharmaceuticals
Target Recruit Count
132
Registration Number
NCT03738865
Locations
🇦🇹

Medizinische Universität Graz-Center for Medical Research, Graz, Austria

🇺🇸

PPD-Las Vegas Clinical Research Unit, Las Vegas, Nevada, United States

🇨🇦

AltaSciences, Montréal, Quebec, Canada

and more 4 locations

Intranasal Glucagon and Energy Balance

Phase 2
Conditions
Obesity
Interventions
Drug: Placebo
First Posted Date
2018-08-28
Last Posted Date
2018-08-31
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
20
Registration Number
NCT03650582
Locations
🇨🇦

Toronto General Hospital, Toronto, Ontario, Canada

Glucagon's Cardiovascular Effects With and Without Beta-blocker-induced Cardioinhibition

Phase 4
Completed
Conditions
Drug Overdose
Overdose of Beta-adrenergic Blocking Drug
Interventions
Drug: Physiologic saline - esmolol dummy
Drug: Physiologic saline - glucagon dummy
First Posted Date
2018-05-23
Last Posted Date
2019-10-17
Lead Sponsor
University Hospital Bispebjerg and Frederiksberg
Target Recruit Count
10
Registration Number
NCT03533179
Locations
🇩🇰

University Hospital Bispebjerg, Copenhagen, Denmark

Hepatic Metabolic Changes in Response to Glucagon Infusion

Not Applicable
Completed
Conditions
Diabetes Mellitus
Non-Alcoholic Fatty Liver Disease
Total Pancreatectomy
Interventions
Drug: Saline
First Posted Date
2018-05-16
Last Posted Date
2019-08-06
Lead Sponsor
Steno Diabetes Center Copenhagen
Target Recruit Count
27
Registration Number
NCT03526445
Locations
🇩🇰

Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark

Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses

Phase 2
Terminated
Conditions
Hypoglycemia Unawareness
Diabetes Mellitus, Type 1
Interventions
Drug: Placebo
First Posted Date
2018-04-06
Last Posted Date
2021-02-21
Lead Sponsor
Xeris Pharmaceuticals
Target Recruit Count
49
Registration Number
NCT03490942
Locations
🇺🇸

University of Alabama, Birmingham, Birmingham, Alabama, United States

🇺🇸

University of California, San Diego, San Diego, California, United States

🇺🇸

Emory University - Grady Memorial Hospital, Atlanta, Georgia, United States

and more 2 locations

First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People.

Phase 1
Completed
Conditions
Diabetes
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Interventions
Drug: NNC9204-1513
Drug: Placebo
First Posted Date
2018-02-23
Last Posted Date
2018-09-05
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
36
Registration Number
NCT03444467
Locations
🇩🇪

Novo Nordisk Investigational Site, Berlin, Germany

G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes

Phase 3
Completed
Conditions
Type 1 Diabetes Mellitus
Severe Hypoglycemia
Insulin Hypoglycemia
Interventions
First Posted Date
2018-02-20
Last Posted Date
2020-02-17
Lead Sponsor
Xeris Pharmaceuticals
Target Recruit Count
81
Registration Number
NCT03439072
Locations
🇺🇸

ProSciento, Inc., Chula Vista, California, United States

🇺🇸

Atlanta Diabetes Associates, Atlanta, Georgia, United States

🇺🇸

Diablo Clinical Research, Inc., Walnut Creek, California, United States

and more 3 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy